Puma Biotechnology (PBYI) Long-Term Deferred Tax (2024 - 2026)

Puma Biotechnology's Long-Term Deferred Tax history runs 3 years deep, the most recent figure standing at $3.8 million for Q1 2026.

• Quarterly Long-Term Deferred Tax fell 45.87% year-over-year to $3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.8 million (down 45.87% YoY) and the FY2025 annual result came in at $3.8 million, down 45.87% from the prior year.
• Long-Term Deferred Tax was $3.8 million for Q1 2026 at Puma Biotechnology, roughly flat from $3.8 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $7.1 million in Q4 2024 and bottomed at $3.8 million in Q4 2025.
• A 3-year average of $6.0 million and a median of $7.1 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Peak annual rise in Long-Term Deferred Tax reached 45.87% in 2025, while the deepest fall reached 45.87% in 2025.
• Puma Biotechnology's Long-Term Deferred Tax stood at $7.1 million in 2024, then plunged by 45.87% to $3.8 million in 2025, then changed by 0.0% to $3.8 million in 2026.
• Business Quant data shows PBYI's Long-Term Deferred Tax at $3.8 million in Q1 2026, $3.8 million in Q4 2025, and $7.1 million in Q3 2025.